<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078910</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000353196</org_study_id>
    <secondary_id>MAYO-229701</secondary_id>
    <nct_id>NCT00078910</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer</brief_title>
  <official_title>A Prospective Phase II Study of Preoperative, Controlled Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as exisulind, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before&#xD;
      surgery may shrink the tumor so that it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well neoadjuvant exisulind works in treating&#xD;
      patients who are undergoing radical prostatectomy for stage II or stage III prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the effect of neoadjuvant exisulind vs no neoadjuvant treatment on apoptosis in&#xD;
           patients with stage II or III prostate cancer undergoing radical prostatectomy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effect of this drug (preoperatively) on surrogate endpoint biomarkers&#xD;
           (i.e., prostate-specific antigen, high-grade prostatic intraepithelial neoplasia, MIB-1,&#xD;
           and DNA ploidy) in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, controlled study. Patients are assigned to 1 of 2 groups&#xD;
      based on the treating physician.&#xD;
&#xD;
        -  Control group: Patients undergo radical prostatectomy only.&#xD;
&#xD;
        -  Treatment group: Patients receive oral exisulind once daily for 4 weeks. Patients then&#xD;
           undergo radical prostatectomy.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 130 patients (65 per group) will be accrued for this study&#xD;
      within approximately 10-12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Apoptosis 4 weeks after completion of study as assessed by marker analysis (bcl-2, Bax, Par-4, M30, TUNEL assay, PTEN)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modulation of other surrogate endpoint biomarkers (prostate-specific antigen high-grade prostatic intraepithelial neoplasia, MIB-1, and DNA ploidy)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exisulind</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Clinical stage T1c-3b, N0-X, M0&#xD;
&#xD;
               -  Gleason score â‰¥ 6&#xD;
&#xD;
          -  Planning to undergo pelvic lymphadenectomy and radical prostatectomy at Mayo Clinic&#xD;
             Rochester&#xD;
&#xD;
               -  Interval from biopsy to prostatectomy is at least 4, but no more than 14, weeks&#xD;
&#xD;
               -  Selected patients of Dr. R. P. Myers who are undergoing prostatectomy during the&#xD;
                  enrollment period will be assigned to the control group* NOTE: *Additional&#xD;
                  historical controls may be selected from Dr. Myers' patients who underwent&#xD;
                  prostatectomy within the past 4 years&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  40 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT normal (10-45 U/L)&#xD;
&#xD;
          -  AST normal (12-31 U/L)&#xD;
&#xD;
          -  Alkaline phosphatase normal (119-309 U/L)&#xD;
&#xD;
          -  Bilirubin normal (0.1-1.0 mg/dL)&#xD;
&#xD;
          -  No history of hepatitis, cirrhosis, or other hepatic dysfunction&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No hypersensitivity to sulindac (treatment group)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior ablation (treatment group)&#xD;
&#xD;
          -  No prior hormone replacement or antiandrogen therapy (e.g., testosterone,&#xD;
             diethylstilbestrol, leuprolide, goserelin, flutamide, bicalutamide, finasteride,&#xD;
             nilutamide, or megestrol)&#xD;
&#xD;
          -  No concurrent antiandrogen therapy, luteinizing hormone-releasing hormone agonists,&#xD;
             finasteride, or diethylstilbestrol&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior treatment for prostate cancer before prostatectomy (control group)&#xD;
&#xD;
          -  No concurrent cyclooxygenase-2 inhibitors&#xD;
&#xD;
          -  No concurrent sulindac&#xD;
&#xD;
          -  No concurrent nonsteroidal anti-inflammatory drugs except low-dose (no more than 325&#xD;
             mg/day) aspirin for cardiovascular prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley C. Leibovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac sulfone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

